CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.220
+0.010 (0.45%)
At close: Mar 10, 2025, 4:00 PM
2.085
-0.135 (-6.08%)
After-hours: Mar 10, 2025, 6:10 PM EST
CervoMed Revenue
CervoMed had revenue of $1.94M in the quarter ending September 30, 2024, with 27.07% growth. This brings the company's revenue in the last twelve months to $10.07M, up 116.29% year-over-year. In the year 2023, CervoMed had annual revenue of $7.14M.
Revenue (ttm)
$10.07M
Revenue Growth
+116.29%
P/S Ratio
1.64
Revenue / Employee
$1,258,319
Employees
8
Market Cap
18.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.14M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRVO News
- 5 weeks ago - CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewsWire
- 3 months ago - CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Benzinga
- 3 months ago - CervoMed's stock craters 77% after failed trial of treatment for rare brain disease - Market Watch
- 3 months ago - CervoMed's dementia drug fails to meet mid-stage trial goals - Reuters
- 3 months ago - CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia - GlobeNewsWire
- 4 months ago - CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire